The European Drug Report 2026: Trends and Developments presents the EUDA’s latest analysis of the drug situation in Europe. Focusing on illicit drug use, related harms and drug supply, the report provides a comprehensive set of national data across these themes, as well as on specialist drug treatment and key harm reduction interventions.

Content
The drug situation in Europe up to 2026
This page draws on the latest data available to provide an overview of the current situation and emerging drug issues affecting Europe, with a focus on the year up to the end of 2025. The analysis presented here highlights some developments that may have important implications for drug policy and practitioners in Europe.

Drug supply, production and precursors
Analysis of the supply-related indicators for illicit drugs in the European Union suggests that availability remains high across all substance types. On this page, you can find an overview of drug supply in Europe based on the latest data, supported by the latest time trends in drug seizures and drug law offences, together with 2024 data on drug production and precursor seizures.

Cannabis
Cannabis remains by far the most commonly consumed illicit drug in Europe. On this page, you can find the latest analysis of the drug situation for cannabis in Europe, including prevalence of use, treatment demand, seizures, price and purity, harms and more. 

Cocaine
Cocaine is, after cannabis, the second most commonly used illicit drug in Europe, although prevalence levels and patterns of use differ considerably between countries. On this page, you can find the latest analysis of the drug situation for cocaine in Europe, including prevalence of use, treatment demand, seizures, price and purity, harms and more.

Synthetic stimulants
Amphetamine, methamphetamine and, more recently, synthetic cathinones are all synthetic central nervous system stimulants available on the drug market in Europe. On this page, you can find the latest analysis of the drug situation for synthetic stimulants in Europe, including prevalence of use, treatment demand, seizures, price and purity, harms and more.

MDMA
MDMA is a synthetic drug chemically related to the amphetamines, but with somewhat different effects. In Europe, MDMA use has generally been associated with episodic patterns of consumption in the context of nightlife and entertainment settings. On this page, you can find the latest analysis of the drug situation for MDMA in Europe, including prevalence of use, seizures, price and purity and more. 

Heroin and other opioids
Heroin remains Europe’s most commonly used illicit opioid and is responsible for a large share of the health burden attributed to illicit drug consumption. Europe’s opioid problem, however, continues to evolve in ways that are likely to have important implications for how we address issues in this area. On this page, you can find the latest analysis of the drug situation for heroin and other opioids in Europe, including prevalence of use, treatment demand, seizures, price and purity, harms and more. 

New psychoactive substances
The market for new psychoactive substances is characterised by the large number of substances that have emerged, with new ones being detected each year. On this page, you can find an overview of the drug situation for new psychoactive substances in Europe, supported by information from the EU Early Warning System on seizures and substances detected for the first time in Europe. New substances covered include synthetic and semi-synthetic cannabinoids, synthetic cathinones, new synthetic opioids and nitazenes.  

Other drugs
Alongside the more well-known substances available on illicit drug markets, a number of other substances with hallucinogenic, anaesthetic, dissociative or depressant properties are used in Europe: these include LSD, hallucinogenic mushrooms, ketamine, GHB and nitrous oxide. On this page, you can find the latest analysis of the situation regarding these substances in Europe, including seizures, prevalence and patterns of use, treatment entry, harms and more.

Injecting drug use
Despite a continued decline in injecting drug use over the past decade in the European Union, this behaviour is still responsible for a disproportionate level of both acute and chronic health harms associated with the consumption of illicit drugs. On this page, you can find the latest analysis of injecting drug use in Europe, including key data on prevalence at national level and among clients entering specialist treatment, as well as insights from studies on syringe residue analysis and more.

Drug-related infectious diseases
People who inject drugs are at risk of contracting infections through the sharing of drug use paraphernalia. On this page, you can find the latest analysis of drug-related infectious diseases in Europe, including key data on infections with HIV and hepatitis B and C viruses.

Drug-induced deaths
Estimating the mortality attributable to drug use is critical for understanding the public health impact of drug use and how this may be changing over time. On this page, you can find the latest analysis of drug-induced deaths in Europe, including key data on overdose deaths, the substances implicated and more. 

Opioid agonist treatment
Opioid users represent the largest group undergoing specialised drug treatment, mainly in the form of opioid agonist treatment. On this page, you can find the latest analysis of the provision of opioid agonist treatment in Europe, including key data on coverage, the number of people in treatment, pathways to treatment and more.

Harm reduction
Harm reduction encompasses interventions, programmes and policies that seek to reduce the health, social and economic harms of drug use to individuals, communities and societies. On this page, you can find the latest analysis of harm reduction interventions in Europe, including key data on opioid agonist treatment, naloxone programmes, drug consumption rooms and more. 

Annex tables:

List of tables

• Opioids
  • Table 1a. High-risk opioid use estimates for the population aged 15 to 64 years
  • Table 1b. Entrants into treatment during the year: opioids clients as a proportion of treatment demands
  • Table 1c. Entrants into treatment during the year: proportion of opioids clients with injection as main route of administration
  • Table 1d. Number of clients in opioid agonist treatment
• Cocaine
  • Table 2a. Cocaine prevalence (percent) estimates among the general population and school students
  • Table 2b. Entrants into treatment during the year: cocaine clients as a proportion of treatment demands
  • Table 2c. Entrants into treatment during the year: proportion of cocaine clients with injection as main route of administration
• Amphetamines
  • Table 3a. Amphetamines prevalence (percent) estimates among the general population and school students
  • Table 3b. Entrants into treatment during the year: amphetamines clients as a proportion of treatment demands
  • Table 3c. Entrants into treatment during the year: proportion of amphetamines clients with injection as main route of administration
• MDMA
  • Table 4a. MDMA prevalence (percent) estimates among the general population and school students
  • Table 4b. Entrants into treatment during the year: MDMA clients as a proportion of treatment demands
• Cannabis
  • Table 5a. Cannabis prevalence (percent) estimates among the general population and school students
  • Table 5b. Entrants into treatment during the year: cannabis clients as a proportion of treatment demands
• Other indicators
  • Table 6. Drug-induced deaths, HIV diagnoses, injecting drug use estimates, take-home naloxone, syringes distributed through specialised programmes
• Seizures
  • Table 7. Seizures data